Overview
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinsonian disorders including Multiple System Atrophy and Parkinson's disease. The company's lead candidate, ATH434, is an oral small molecule that inhibits alpha-synuclein aggregation by targeting excess iron accumulation in the central nervous system through an iron-chaperone mechanism. Alterity's therapeutic approach addresses fundamental pathological mechanisms underlying neurodegeneration, with the mission to improve clinical outcomes and quality of life for patients with progressive neurological disorders.